Strikingly, combinatorial blockade of HMGA2 and CD47 checkpoint (anti-CD47 mAb 1 mg/kg biweekly, the main function is to enhance the phagocytic activity of macrophages towards tumor cells) synergistically amplified antitumor efficacy, achieving near-complete regression (85.1% suppression; p<0.001 vs monotherapies), establishing dual-targeting strategy as a promising therapeutic paradigm (Figures 7B–D). The gene discussed is HMGA2; the disease is neoplasm.